



## **Press Release**

### **STADA acquires UK branded product company Natures Aid**

Bad Vilbel, November 21, 2016 – STADA UK Holdings acquires Natures Aid, a family-owned UK based branded product company. The company is an established manufacturer of vitamins, minerals, food supplements and herbal products distributed under the Natures Aid brand. Until 2020, the global dietary supplement market is expected to grow by about 5% annually.<sup>1</sup> Over the past years, the company posted double-digit sales growth annually (3yr-CAGR: ~14%).

Natures Aid, based in Preston, UK, was founded in 1981 and currently has approximately 60 employees. In the financial year July 2015 to June 2016 Nature Aid posted sales of GBP 7.3 million (approximately Euro 8.5 million), of which approximately 80% are generated in UK and 20% in more than 40 countries worldwide. EBITDA was GBP 1.9 million.

“With Natures Aid we acquire a leading company in the attractive UK food supplement market which is also well recognized in its international markets for its high quality standards. The acquisition not only matches our financial investment criteria perfectly. It also represents a highly synergetic fit to our Thornton & Ross business in UK to further strengthen our product portfolio in the attractive branded business, in line with our overall company strategy.”, says CEO Dr. Matthias Wiedenfels.

The acquisition will be closed and consolidated as of November 21, 2016.

#### **About STADA Arzneimittel AG**

STADA Arzneimittel AG is a publicly-listed company with headquarters in Bad Vilbel, Germany. STADA consistently focuses on a multi-pillar strategy of generics and branded products (OTC) with an increasingly international market orientation. The Group is the only independent generics

---

<sup>1</sup> Source: Persistence Market Research: Global Market Study on Dietary Supplements, April 2015



producer in Germany. STADA is represented in more than 30 countries with approximately 50 sales companies worldwide. Branded products such as Grippostad and Ladival are among the highest selling in their product category in Germany. In financial year 2015, STADA achieved Group sales of Euro 2,115.1 million, adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of Euro 389.4 million and adjusted net income of Euro 165.8 million. As of December 31, 2015, STADA employed 10,532 people worldwide.

**Additional information for journalists:**

STADA Arzneimittel AG / Media Relations / Stadastraße 2–18 / 61118 Bad Vilbel /

Phone: +49 (0) 6101 603-165 / Fax: +49 (0) 6101 603-215 / E-Mail: [press@stada.de](mailto:press@stada.de)

Or visit us online at [www.stada.de](http://www.stada.de).

Executive Board: Dr. Matthias Wiedenfels (Chairman) / Helmut Kraft

Chairman of the Supervisory Board: Carl Ferdinand Oetker